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Purpose: To assess the therapeutic response for metastatic breast cancer with 18F-
FDG position emission tomography (PET), this retrospective study aims to compare the 
performance of six different metabolic metrics with PERCIST, PERCIST with optimal 
thresholds, and an image-based parametric approach.
Methods: Thirty-six metastatic breast cancer patients underwent 128 PET scans and 
123 lesions were identified. In a per-lesion and per-patient analysis, the performance 
of six metrics: maximum standardized uptake value (SUVmax), SUVpeak, standardized 
added metabolic activity (SAM), SUVmean, metabolic volume (MV), total lesion glycolysis 
(TLG), and a parametric approach (SULTAN) were determined and compared to the 
gold standard (defined by clinical assessment and biological and conventional imaging 
according RECIST 1.1). The evaluation was performed using PERCIST thresholds (for 
per-patient analysis only) and optimal thresholds (determined by the Youden criterion 
from the receiver operating characteristic curves).
results: In the per-lesion analysis, 210 pairs of lesion evolutions were studied. Using 
the optimal thresholds, SUVmax, SUVpeak, SUVmean, SAM, and TLG were significantly 
correlated with the gold standard. SUVmax, SUVpeak, and SUVmean reached the best 
sensitivity (91, 88, and 83%, respectively), specificity (93, 95, and 97%, respectively), 
and negative predictive value (NPV, 90, 88, and 83%, respectively). For the per-patient  
analysis, 79 pairs of PET were studied. The optimal thresholds compared to the PERCIST 
threshold did not improve performance for SUVmax, SUVpeak, and SUVmean. Only 
SUVmax, SUVpeak, SUVmean, and TLG were correlated with the gold standard. 
SULTAN also performed equally: 83% sensitivity, 88% specificity, and NPV 86%.
conclusion: This study showed that SUVmax and SUVpeak were the best parameters 
for PET evaluation of metastatic breast cancer lesions. Parametric imaging is helpful in 
evaluating serial studies.
Keywords: FDg, PeT, breast cancer, PercisT, therapeutic evaluation, parametric analysis, sUlTan
Abbreviations: AUC, area under curve; EORTC, European Organization for Research and Treatment of Cancer; FADS, factor 
analysis of dynamic sequences; FDG, fluorodeoxyglucose; FN, false negative; FP, false positive; MRI, magnetic resonance 
imaging; MV, metabolic volume; NPV, negative predictive value; PET, positron emission tomography; PPV, positive predictive 
value; ROC, receiver operating characteristic; ROI, region of interest; SAM, standardized added metabolic activity; SULTAN, 
longitudinal monitoring in positron factor analysis; SUL, SUV lean body mass; SUV, standard uptake value; TLG, total lesion 
glycolysis; TN, true negative; TP, true positive.
2Goulon et al. Breast Metastatic Response by PET
Frontiers in Medicine | www.frontiersin.org May 2016 | Volume 3 | Article 19
inTrODUcTiOn
Metastatic breast cancer is initially diagnosed in 6–10% of cases 
and during follow-up in 30% of cases (1). The treatment strategy 
in this situation is mainly based on chemotherapy, hormonal 
therapy, targeted therapies, and possibly external radiotherapy. 
The accurate and early assessment of therapeutic efficacy repre-
sents a major challenge but is crucial for limiting toxicity and 
reducing expensive treatments.
Current therapeutic responses for solid tumors are conven-
tionally assessed using the international standard RECIST 1.1 (2). 
However, RECIST has a number of intrinsic limitations such as 
moderate reproducibility of tumor measurement (3), late occur-
rence of morphological response compared to early metabolic 
changes, not applicable with non-measurable morphological 
lesions (bone lesions, lymphangitis, and effusions), and in targeted 
cytostatic therapies. Functional imaging by position emission 
tomography (PET) with 18-fluorodeoxyglucose (18FDG) repre-
sents a potential alternative (4, 5). Specific evaluation criteria for 
metabolic responses have been previously defined. These include 
measures of quantitative metrics and visual analysis tools to clas-
sify tumor progression and response, as defined by the European 
Organization for Research and Treatment of Cancer (EORTC) 
(6) or PERCIST (3).
The 18FDG-PET showed interest in breast cancer management 
(7), for initial staging of locally advanced cancers (stages II–III) 
and/or inflammatory lesions (8), detection of recurrence with 
better performance than conventional imaging (7, 9, 10), evalu-
ation of therapeutic response to neo-adjuvant therapy in inoper-
able locally advanced cancers or before conservative surgery or 
inflammatory lesions (7, 11), and therapy evaluation in metastatic 
disease (5, 12–18). However, although 18FDG-PET proved inter-
est in several clinical studies, it is not used in clinical practice 
for therapy assessment because of the lack of standardization of 
imaging interpretation (12). Some studies suggested a benefit of 
using semi-quantitative analysis (mainly the change in SUVmax 
or SUVmean between two PET scans) rather than visual analysis 
only. However, the best metric and optimal threshold was not 
clearly defined. Moreover, it is worth noting that none of these 
studies were based on the PERCIST approach proposed by Wahl 
et al. (3).
Semi-quantitative methods (3–6) have been proposed for 
therapeutic evaluation using PET to improve reproducibility 
based on the percentage variation of a metric (SUVmax for 
EORTC and SULpeak for PERCIST). Yet, they have not been 
validated in the context of specific tumors, especially breast can-
cer (12). Moreover, some requirements of PERCIST (mainly need 
for a tumor size >2 cm and no difference between liver signal 
between the two PET scans) may be difficult to achieve in clinical 
practice.
New evaluation methods based on parametric analysis are also 
being developed, while the best metrics and optimal thresholds 
were not clearly defined (19). The SULTAN (longitudinal moni-
toring in tomography using factor analysis) method, for example, 
proposes a novel semi-automatic method to assist in tumor 
response assessment by studying the metabolic change at the 
voxel level (20, 21). SULTAN provides a parametric map of the 
tumor metabolic change using two or more PET scans and allows 
the heterogeneity of response within the tumor to be determined.
The first objective of this retrospective study was to compare 
the performance of different metabolic metrics on a per-lesion 
and per-patient basis in the assessment of therapeutic response 
in metastatic breast cancer.
The second objective was to assess the benefit of parametric 
imaging (SULTAN) in this population.
MaTerials anD MeThODs
Patients and imaging Protocols
For this single center study conducted from September 2009 to 
July 2014, 36 patients (median age 63.5 years, range: 39–85 years) 
with breast cancer of any histological grade and metastatic 
involvement (i.e., initially metastatic or metastatic following 
diagnostic evaluation), underwent at least two 18FDG-PET scans 
using the same PET system in the course of their therapy. Tumor 
phenotypes were classified as 26 invasive ductal carcinomas, 6 
invasive lobular carcinomas, 3 intraductal carcinomas, and 1 
colloid carcinoma. Twenty-eight tumors were estrogen receptor 
(ER) positive, 21 progesterone receptor (PR) positive, 4 HER2 
over-expression (HER2), and 6 were triple-negative. Treatments 
consisted of adjuvant chemotherapy, hormonal therapies, targeted 
therapies, Herceptin, and/or radiotherapy. A total of 128 PET 
scans were acquired (median of 3 PET/patient, range: 2–9) with 
a median time interval of 3.7 months between two PET (range: 
1.1–19.6). A total of 123 lesions were analyzed: 44 lymph nodes, 
43 bone lesions, 17 liver lesions, 10 breast lesions, 5 lung lesions, 
and 4 peritoneal carcinomatosis. A total of 79 pairs of PET scans 
were analyzed in 36 patients.
Position emission tomography scans were conducted in patients 
fasted for at least 6 h, with normal blood glucose <10 mmol/L, 
1  h after injection of 3 or 7  MBq/kg of 18FDG (depending on 
the PET system used), using either a Siemens Biograph mCT 40 
camera (Siemens Healthcare Molecular Imaging USA, Inc.) or a 
General Electric Discovery LS (GE Medical Systems, Waukesha, 
WI, USA). The low-dose computed tomography acquisition was 
performed first without injection of iodinated contrast agent, fol-
lowed by PET acquisition using 3 min per bed position (Siemens 
Biograph mCT) or 5 min for the GE Discovery LS. The following 
acquisition constraints according to the PERCIST framework 
were respected: similar activity between each PET scan (±20%), 
standardization against normal liver, and a similar delay between 
injection and acquisition (50–70 min after injection).
image analysis Using semi-Quantitative 
Metrics
Six PET-based metrics were derived, for a maximum of five tumor 
targets (maximum of two targets per organ) as recommended by 
PERCIST (3): SUVmax, SUVpeak, SUVmean, metabolic volume 
(MV), total lesion glycolysis (TLG  =  SUVmean  ×  MV), and 
standardized added metabolic activity (SAM) (22). SAM was 
proposed to overcome the partial volume effect. The segmenta-
tion approach proposed by Schaefer was used for computing 
SUVmean, MV, and TLG (23).
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The gold standard was defined by clinical assessment, and 
biological and conventional imaging by CT and MRI, performed 
3 weeks after the PET evaluation. RECIST 1.1 (2) was used in these 
assessments. Each evolution was classified as either a responder 
or non-responder according to the gold standard.
A “responder” as assessed by PET was defined as a metric 
decrease greater than the threshold, while a “non-responder” 
was defined as a decrease of less than the threshold or an increase 
in the metrics. The four different types of response were true 
positive (TP), responder according to PET and the gold standard; 
true negative (TN), non-responder according to PET and the gold 
standard; false negative (FN), non-responder according to PET 
but responder according to the gold standard; and false positive 
(FP), responder according to PET but non-responder according 
to the gold standard.
image analysis Using Parametric imaging 
(sUlTan)
SULTAN is a parametric approach that compares two or more 
PET scans acquired before and during therapy (20, 21). In the 
context of this study, pairs of PET volumes acquired for the same 
patient were considered.
This new approach involves a rigid registration between the 
two PET scans, followed by a factor analysis as briefly described 
in the following sections.
Registration of PET Volumes
To compare two PET images at a voxel level, these scans first 
need to be registered so that a given voxel corresponds to the 
same volume element in each of the two scans. The method used 
was described in Ref. (24). Briefly, the CT volumes were used to 
determine the appropriate transformation for aligning the PET 
images, as they include far more anatomical details for guiding 
registration than the PET images. The two CT volumes of inter-
est (VOIs) were registered using a rigid transformation (three 
translation and three rotation parameters) derived from block-
matching registration (19) as implemented in the Planet Onco 
software (Dosisoft). Local rigid transformation was assumed 
as only the region including mass was actually registered. The 
transformation mapping the second CT volume onto the first CT 
volume was then applied to the second PET scan so as to align it 
with the first PET scan, assuming the PET and CT of a given scan 
were perfectly registered.
Calculation of Parametric Image of Significant 
Tumor Changes
The two registered PET scans, denoted as PET1 and PET2, were 
analyzed using a factor analysis of dynamic sequences (FADS) 
approach (25) as implemented in the software Pixies [Apteryx, 
2004]. The algorithm assumes that the two-component vector 
S(v, t) measured in each voxel (one value for the first scan and one 
value for the second scan) is a weighted sum of K basis functions. 
In this algorithm, the number K is constrained by the number 
of PET scans, hence is equal to 2. Let S(v, t) be the signal 
recorded at the voxel v for the time t (t = 1, 2). Then,
 S(v, t) = Ib (v).Cb(t) + Ie (v).Ce(t) + e(v, t) (1)
where Cb(t) and Ce(t) are two basis kinetics, Ib is the spatial distri-
bution of the voxel component following the Cb time course, Ie is 
the spatial distribution of the voxel component following the Ce 
time course, and e(v, t) is an additive error term. Factor analysis 
estimates the two functions Cb(t) and Ce(t), called factors, and 
their associated images Ib(v) and Ie(v), called factor images.
Equation  1 is solved using a principal component analysis 
followed by an oblique rotation under a constant function con-
straint representing the constant voxels of the background (Cb) 
and without any other constraint on Ib(v) and Ie(v). The algorithm 
iteratively estimates the two factors, Cb and Ce, and the associated 
factor images, Ib and Ie (25). Therefore, the voxels that evolved 
between the two scans followed the Ce factor.
A new image (SULTAN image) is then created whereby each 
pixel v is equal to Ie(v) if |Ie(v)| > 1 or 0 otherwise. Hence, each 
voxel reflects its evolution over time following the Ce factor 
(Ie > 0) or the opposite direction of Ce (Ie < 0).
Finally, each lesion was classified as responder (main factor 
decreasing with Ie > 0 or main factor increasing with Ie < 0) or 
non-responder (main factor increasing with Ie > 0 or main factor 
decreasing with Ie < 0). Patient was considered as responder if 
all lesions were responders and non-responder otherwise. The 
results were then classified as VP, VN, FP, and FN by comparison 
with the gold standard.
statistical analysis
The study was performed using a per-lesion and a per-patient 
analysis. For each analysis, the metrics were compared using the 
area under the curve (AUC) determined with receiver operating 
characteristic (ROC) analysis.
The optimal thresholds were derived using the Youden 
criterion [max (sensitivity + specificity − 1)] through the ROC 
analysis for the per-lesion and per-patient studies.
The per-lesion analysis was performed using the percentage 
change using optimal threshold of each metabolic metric. Each 
lesion was then compared with the gold standard.
The per-patient analysis was performed using the PERCIST 
criteria (the percentage change of each metabolic metric for the 
most intense lesion in each PET between two scans). The per-
centage change was interpreted as responder or non-responder 
using previously optimized thresholds but also using PERCIST 
threshold (30% for each metric, except 45% for TLG). Each pair 
of PET scans was then compared with the gold standard.
The sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and accuracy were then calcu-
lated for each index.
Pearson’s chi-squared analysis with a type I error of 0.05 and 
1 degree of freedom was performed to determine significant 
associations between the different quantitative metrics and the 
gold standard.
Statistical significance was set to p < 0.05. Statistical analysis 
was performed using MedCalc Statistical Software version 14.12.0 
(MedCalc Software, Ostend, Belgium; http://www.medcalc.org; 
2014).
We obtained informed consent from all patients allowing the 
use of their clinical data for research purposes under a protocol 
approved in our institution.
FigUre 2 | synthetic scheme of the results of the intercomparison 
per-lesion study. Indices lying in the same circle were not significantly 
different.
TaBle 1 | Metabolic metrics aUc for per-lesion analysis.
Metrics sUVmax sUVpeak sUVmean saM MV Tlg
AUC 0.960 0.958 0.937 0.775 0.554 0.822
FigUre 1 | rOc curves of metabolic indices for per-lesion analysis.
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resUlTs
Per-lesion analysis Using Quantitative 
Metrics
A total of 123 lesions and 210 pairs of lesion evolutions, fol-
lowed on two to nine scans, were analyzed with 111 considered 
as responders and 99 as non-responders according to the gold 
standard.
Figure 1 shows the results of the ROC study for the six metrics. 
The AUC values (Table 1) ranged from 0.55 for MV to 0.96 for 
SUVmax. The AUC intercomparison study distinguished three 
significantly distinct groups: SUVmax/SUVpeak/SUVmean, 
SAM/TLG, and MV (Figure 2).
The optimal thresholds defined by the Youden criterion, were 
21% for SUVmax, 23% for SUVpeak, 29% for SUVmean, 48% for 
SAM, 33% for MV, and 20% for TLG.
Sensitivity, specificity, PPV, NPV, accuracy values, and Youden 
correlation coefficients were calculated for their optimal thresh-
old (Table 2).
Five metrics (SUVmax, SUVpeak, SUVmean, SAM, and TLG) 
significantly correlated with the gold standard (p < 0.05), but the 
analysis of correlation coefficients (Youden index) showed that 
SUVmax, SUVpeak, and SUVmean led to the best performance in 
terms of sensitivity (91, 88, and 83%, respectively), specificity (93, 
95, and 97%, respectively), and NPV (90, 88, and 83%, respectively).
Per-Patient analysis Using Quantitative 
Metrics
A total of 79 pairs of PET scans were analyzed using the PERCIST 
criteria (the most intense lesion in each PET between two scans) 
with 36 responders and 43 non-responders.
The AUC (Figure 3; Table 3) ranged from 0.61 for MV to 0.95 
for SUVpeak. The AUC of SUVpeak, SUVmax, SUVmean, TLG, 
and SAM were significantly different from MV (p < 0.05) but not 
between each other (Figure 4).
The percentage change of each metabolic metric was also 
interpreted as responder or non-responder according to the 
choice of the threshold (PERCIST or optimal) and then compared 
with the gold standard.
With PERCIST thresholds (30% for each metric, except 45% 
for TLG), only SUVmax, SUVpeak, and SUVmean were signifi-
cantly correlated with the gold standard (p < 0.05) (Table 4).
The best thresholds were 36% for SUVmax, 26% for SUVpeak, 
29% for SUVmean, 54% for SAM, 58% for MV, and 27% for TLG.
After applying these optimized thresholds, the four metrics 
(SUVpeak, SUVmax, SUVmean, and TLG) were correlated with 
the gold standard (Table  5). Threshold optimization did not 
change the specificity of SUVmax (98 vs. 95%). The sensitivity 
using SUVpeak was slightly improved (72 vs. 67%) with a similar 
NPV (81 vs. 78%). The sensitivity, NPV, and accuracy of TLG were 
improved (53 vs. 36%, 72 vs. 65%, and 78 vs. 71%, respectively).
Figure  5 highlights the benefit of using quantitative PET-
derived metrics for a metastatic bone patient. CT images failed to 
correctly classify the therapeutic response, with the persistence of 
an osteo-condensation even though there was a primary tumor 
response, thus highlighting the fact that bone lesions cannot be 
evaluated using RECIST 1.1.
Per-lesion and Per-Patient analysis Using 
sUlTan
For the per-lesion analysis, results obtained with SULTAN (lon-
gitudinal monitoring in positron factor analysis) were compared 
with those obtained using SUVmax, SUVpeak, and SUVmean. No 
significant difference was found between the assessment of thera-
peutic response by the gold standard and SULTAN (p < 0.05).
For the per-patient PET analysis, SULTAN was compared with 
SUVmax, SUVpeak, and SUVmean, which appeared to be the only 
metrics significantly correlated to the gold standard. SULTAN 
presented no significant difference with SUVmax, SUVpeak, and 
FigUre 3 | rOc curves of metabolic indices for per-patient analysis.
TaBle 2 | comparison of metabolic metrics for per-lesion analysis with optimal thresholds.
Metrics sUVmax sUVpeak sUVmean saM MV Tlg sUlTan
Threshold (%) −21 −23 −29 −48 −33 −20
Sensitivity (%) 91 88 83 66 27 68 86
Specificity (%) 93 95 97 83 89 86 75
PPV (%) 94 95 97 81 73 84 79
NPV (%) 90 88 83 68 52 70 83
Accuracy (%) 92 91 90 74 56 76 81
Youden correlation coefficient 0.84 0.83 0.80 0.49 0.16 0.53 0.61
Significance (χ2p < 0.05) S S S S NS S S
Significance: correlation between the metric and the gold standard according to Youden correlation coefficient.
FigUre 4 | synthetic scheme of the results of the intercomparison 
per-patient study. Indices lying in the same circle were not significantly 
different.
TaBle 4 | comparison of metabolic metrics for per-patient analysis 
according to PercisT threshold.
Metrics sUVmax sUVpeak sUVmean saM MV Tlg
Threshold (%) −30 −30 −30 −30 −30 −45
Sensitivity (%) 75 67 67 39 8 36
Specificity (%) 95 98 95 95 100 100
PPV (%) 93 96 92 88 100 100
NPV (%) 82 78 77 65 57 65
Accuracy (%) 86 84 82 70 58 71
Youden 
correlation 
coefficient
0.70 0.64 0.62 0.34 0.08 0.36
Significance 
(χ2 p < 0.05)
S S S NS NS NS
TaBle 3 | Metabolic metrics aUc for per-patient analysis.
Metrics sUVmax sUVpeak sUVmean saM MV Tlg
AUC 0.928 0.952 0.914 0.851 0.606 0.876
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SUVmean results using the PERCIST threshold (sensitivity: 83 
vs. 75, 72, and 67%; NPV: 86 vs. 82, 81, and 77%, respectively). 
However, specificity and PPV were found to be lower than 
quantitative metrics (specificity: 88 vs. 98, 98, and 95%; PPV: 86 
vs. 96, 96, and 92%) (Table 6). Figures 6 and 7 show an example 
of a responder and a non-responder patient using SULTAN.
DiscUssiOn
Considering the limitations of morphological criteria and the 
subjectivity of visual analysis of metabolic imaging in the field of 
therapeutic evaluation, the use of quantitative PET-based metrics 
has gained interest in recent years (3, 7, 11–17, 26, 27). Depending 
on the disease studied, various metrics and thresholds have been 
established. In breast cancer, the majority of studies evaluating 
therapeutic response by metabolic metrics have been made in 
a neo-adjuvant setting, with histological confirmation, the true 
gold standard. In the adjuvant setting, the overall therapeutic 
response is usually assessed using morphological and metabolic 
imaging, and biological and clinical exams (7).
The choice of a preferred biomarker differs between neo-
adjuvant and adjuvant settings. In the neo-adjuvant setting, with 
a curative intent, the NPV is the preferred relevant statistical 
information in early detection of non-responders before a change 
of therapy. In the adjuvant setting for metastatic patients, false-
negative PET may lead to a treatment change. This was designed 
to counteract a false-positive that may lead to a reduced survival. 
In this situation, choosing the best couple sensitivity–specificity 
may be considered as an acceptable compromise.
It has been reported that a decrease of SUVmax or SUVmean 
after one or two cycles of chemotherapy was significantly 
FigUre 5 | example of metabolic assessment in a patient with metastatic bone evolution. (a) First examination: initial evaluation with multiple bone lesions 
(SUVmax = 11.8; SUVpeak = 7.1); (B) second examination: partial metabolic response on bone (SUVmax = 3.4 or 71% decrease; SUVpeak = 1.5 or 78% 
decrease); and (c) third examination: disease progression with new lesions and recurrence of some initial hypermetabolic lesions (SUVmax = 6.4 or 46% increase; 
SUVpeak = 4.3 or 65% increase). Persistence of sclerosis on all CT images does not allow to evaluate the response.
TaBle 5 | comparison of metabolic metrics and sUlTan for per-patient analysis according to optimized thresholds.
Metrics sUVmax sUVpeak sUVmean saM MV Tlg sUlTan
Threshold (%) −36 −26 −29 −54 −58 −27
Sensitivity (%) 75 72 67 39 8 53 83
Specificity (%) 98 98 95 98 100 100 88
PPV (%) 96 96 92 93 100 100 86
NPV (%) 82 81 77 66 57 72 86
Accuracy (%) 87 86 82 71 58 78 86%
Youden correlation coefficient 0.73 0.70 0.62 0.37 0.08 0.53 0.72
Significance (χ2 p < 0.05) S S S NS NS S S
TaBle 6 | comparison of best metabolic metrics according to PercisT and optimized thresholds and sUlTan for per-patient analysis.
Metrics sUlTan sUVmax sUVpeak sUVmean
−30% PercisT −36% −30% PercisT −26% −30% PercisT −29%
Sensitivity (%) 83 75 75 67 72 67 67
Specificity (%) 88 95 98 98 98 95 95
PPV (%) 86 93 96 96 96 92 92
NPV (%) 86 82 82 78 81 77 77
Accuracy (%) 86 86 87 84 86 82 82
Youden correlation coefficient 0.72 0.70 0.73 0.64 0.70 0.62 0.62
Significance (χ2 p < 0.05) S S S S S S S
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correlated with a successful therapeutic response in the neo-
adjuvant setting (7, 28–32). The optimal thresholds reported in 
these studies for discriminating responder and non-responder 
in per-patient analysis varied from 26 to 58%. These differences 
can be partly explained by the lack of consensus for the defini-
tion of responder and non-responder status (decrease in tumor 
mass >50% by histology or residual microscopic lesions), the 
population heterogeneity between studies (presence of hormone 
receptors, HER2 amplification, etc.), the time of PET completion 
(one, two, or three cycles of chemotherapy), and the criteria used 
to determine the best threshold.
However, only a few studies have used PET scans for evaluat-
ing the treatment response in the context of adjuvant therapy. 
Couturier et  al. (15) showed that a decrease of SUVmax or 
SUVmean was predictive of therapeutic response after three 
cycles of chemotherapy using the same gold standard considered 
in our study. They speculated that response assessment using 
metabolic metrics appeared to be superior to visual analysis. The 
SUV decrease ranged from 52 to 56% for responders and 16 to 
26% for non-responders. Dose Schwarz et al. (17) found that a 
SUVmax reduction of 72 ± 21% after one cycle and 54 ± 16% 
after two cycles of chemotherapy was predictive of response to 
FigUre 6 | (a) Example of non-responder patient classified by SULTAN. First PET showed right hilar hypermetabolism, and second PET performed in therapeutic 
monitoring (exam 2) showed a progression with persistence of right hilar hypermetabolism and the appearance of a hypermetabolic right lung uptake. The evolution 
was classified as non-responder. Factorial image obtained by SULTAN was superimposed on the CT-scan 1 (B). Associated curves (c) represented the growing 
trend (red) or stable (blue) voxels. The developments described by factor analysis were similar to those of SUVmax (D) with a stability of hilar fixation and the 
appearance of a right pulmonary uptake.
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treatment. Furthermore, Specht et al. (16) and Tateishi et al. (18) 
concluded that a decrease of SUVmean, and to a lesser extent 
of TLG for bone metastases, was predictive of the duration of 
response to treatment. In the study of Tateishi (18), a SUVmean 
decrease ≥8.5% was a factor significantly related to the duration 
of response, while the TLG did not. Huyge et al. (33) highlighted 
the significant heterogeneity of the metabolic response for the 
same patient when considering the types of metastases (bone or 
visceral). Using the change of SUVmax, according to the EORTC 
criteria, they highlighted a poorer therapeutic response for bone 
lesions. Finally, Quon and Gambhir (34) has warned that the 
“paradoxical metabolic flare,” which corresponds to an increase of 
SUV in the first 10 days after commencement of hormone therapy, 
may be misconstrued as a sign of an early metabolic reaction.
In our study, SUVmax, SUVpeak, and SUVmean were the most 
efficient metrics in the per-lesion and per-patient analysis. These 
observations are consistent with previously published results, which 
suggest the use of SUVmax (EORTC) or SULpeak (PERCIST). 
The SUVmax measurement is susceptible to be affected by noise 
due to its single-voxel determination (35). The use of SUVpeak 
may overcome this limitation and has been recommended as a 
more robust alternative due to its fixed volume of 1 cm3, therefore 
being less susceptible to noise than SUVmax. However, several 
definitions of SUVpeak are found in the literature differing in 
shape, size, and location of ROIpeak (36). As outlined in Section 
“Introduction,” many requirements imposed by the PERCIST cri-
teria may be considered as too restrictive and difficult to apply in 
routine clinical situations. This is why we evaluated a “PERCIST-
like” method with a SUV normalization against the mass of the 
patient (SUVpeak) rather than the lean body mass normalization 
(SULpeak) as recommended by PERCIST. The small size of the 
majority of measured lesions in our study, less than 2 cm, leads 
to a calculation of SUVpeak heavily weighted on SUVmax, thus 
explaining the high similarity of the results of the two indices.
The SUVmean index gave results similar to SUVmax and 
SUVpeak for the per-patient analysis, also explained by the small 
size of the measured lesions.
The SAM index was less efficient in our study and did not 
demonstrate benefit in our population. This index corresponds to 
the total excess SUV above the tumor background, reducing the 
impact of partial volume effect and lesion segmentation errors. 
Yet, Mertens et al. (22) reported good results with no significant 
difference with SUVmax in patients with colorectal cancer with 
progression to liver metastasis. The optimal threshold for differ-
entiating responders and non-responders was set at 94.5 vs. 25.3% 
for the SUVmax, which is different from our results (54 vs. 36%).
Additionally, we showed that MV and TLG failed to correctly 
classify patients. In this respect, MV performance was variable: 
the approach to this calculation differs among centers with the use 
of gradients, thresholds, or adaptive method. In the neo-adjuvant 
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therapy evaluation of breast cancer by 18F-FDG, Hatt et al. (37) 
found that TLG or MV, determined by a fuzzy locally adapted 
Bayesian algorithm, were better predictors than SUVmax, but the 
lesions they considered were larger than in our study. In our study, 
an adaptive method based on that described by Schaefer (23) 
was used, but it failed to correctly delineate the lesion when the 
signal-to-noise ratio was poor, explaining the poor  performance 
of volume-based metrics.
Parametric imaging was found to be relevant in assessing the 
therapeutic response in breast cancer, with similar performance 
to SUVmax or SUVpeak. SULTAN has already been successfully 
assessed in patients with colorectal cancer and non-small lung cell 
carcinoma (20). SULTAN appears to be a valuable visual tool in 
routine clinical practice because of the otherwise tedious nature of 
measuring numerous lesions. Furthermore, using a single series 
of images, SULTAN provides a summary of all tumor evolutions 
from various scans without arbitrary threshold adjustment.
cOnclUsiOn
Even if our study has limitations (heterogeneous population with 
patients in either first-line or advanced treatment, with varied 
histological and phenotypic characteristics and different treat-
ments), the results underline the importance of the metrics choice 
for PET evaluation. SUVmax, SUVpeak, and to a lesser extent 
SUVmean appeared to be the most relevant metrics. In addition, 
parametric analysis using the SULTAN approach is a reliable tool 
to guide visual interpretation. The poor performances of volu-
metric metrics underline the need for developing and validating 
a robust delineation method that could be applied in the context 
of small lesion with a poor signal-to-noise ratio. In the future, a 
comparison of metrics could be conducted in a prospective study 
performed in a homogeneous population.
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FigUre 7 | example of responder patient classified by sUlTan. First PET showed right axillary lymph nodes hypermetabolism and the second PET, 
performed during therapeutic monitoring (review 2), showed a disappearance of the right axillary hypermetabolism. Factorial image obtained by SULTAN was 
superimposed on the CT-scan 1 (B). Associated curves (c) represented the downward trend (green) or stable (blue) voxels. The developments described by factor 
analysis were similar to those of SUVmax (D) with a loss of the right axillary uptake.
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